Immunogenicity and Safety of the ExPEC9V <i>Escherichia coli</i> Vaccine Co-Administered with a High-Dose Influenza Vaccine in Older Adults: A Placebo-Controlled, Randomized, Phase 3 Study

Background: ExPEC9V is a 9-valent vaccine candidate designed to prevent invasive <i>Escherichia coli</i> disease, a life-threatening condition occurring when extraintestinal pathogenic <i>E. coli</i> (ExPEC) invade sterile sites. We evaluated immunogenicity and safety when ExPEC9V was co-administere...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Isabel Leroux-Roels, Tracey A. Day, Sofie Deleu, Chelsea McLean, Oscar Go, Todd A. Davies, Jeroen N. Stoop, Monika Peeters, Maria G. Pau, Bart Spiessens, Michal Sarnecki, Keira A. Cohen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2026-01-01
coleção:	Vaccines
Assuntos:	clinical trial <i>Escherichia coli</i> ExPEC9V high-dose influenza vaccine invasive <i>E. coli</i> disease O-serotypes
Acesso em linha:	https://www.mdpi.com/2076-393X/14/2/146
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!